Immunicum is continously looking for partnership opportunities with actors in the pharmaceutical industry, mainly with companies that are in need of an effective adjuvant to combine their antigens with.

The company has received a letter-of-intent from UK-based Cancer Vaccine Institute (CVI), stating that CVI is interested in co-funding and conducting a clinical phase I/II trial in melanoma using Immunicum's COMBIG-concept.

As of today, Immunicum also collaborates with several other organizations such as Uppsala Clinical Research (clinical trials), Adlego Biomedical (preclinical studies), and Scandinavian Regulatory Services (regulatory issues).